Impact of cardiac resynchronization therapy optimization inside a heart failure programme: a real-world experience
Thibaut Moulin1, David Hamon1, Kamila Djouadi1
1Department of Cardiology, FHU SENEC, AP-HP, University Hospital Henri Mondor, Créteil, France.
Insights
A cardiac resynchronization therapy (CRT) optimization program showed that while many non-responders improved, echo-guided adjustments to atrioventricular (AVd) and interventricular delays (VVd) did not significantly impact outcomes. Comprehensive follow-up is crucial for CRT patients.
Area of Science:
- Cardiology
- Heart Failure Management
- Medical Device Technology
Background:
- Cardiac Resynchronization Therapy (CRT) is a treatment for heart failure (HF) that can improve symptoms and outcomes.
- However, a significant portion of patients do not respond to CRT, necessitating optimization strategies.
- In-hospital CRT programs aim to improve patient management and device efficacy.
Purpose of the Study:
- To evaluate the impact of a routine in-hospital CRT program.
- To assess the effectiveness of comprehensive HF evaluation and echo-guided CRT optimization.
- To identify factors influencing CRT response and outcomes.
Main Methods:
- A cohort of 227 CRT-implanted patients underwent an optimization program 3-12 months post-implantation.
- The program included clinical/biological assessment, screening for non-response causes, and echo-guided optimization of atrioventricular (AVd) and interventricular delays (VVd).
- Clinical response was assessed using a composite score (CCS) at 6 months, and major HF events were tracked for 1 year.
Main Results:
- Of 227 patients, 111 (48.9%) were initial non-responders.
- Among 196 patients optimized, 36.2% required VVd modification and 34.7% required AVd modification.
- At 6 months, 34.3% of initial non-responders improved, but AVd/VVd modifications were not significantly linked to CCS improvement. Initial non-responders had more HF events over 1 year.
Conclusions:
- A close, comprehensive, and multidisciplinary follow-up is essential for CRT patients.
- The study does not advocate for the routine use of echo-guided CRT optimization.
- Further research may be needed to refine CRT optimization strategies for non-responders.
Aims:
This study sought to describe and evaluate the impact of a routine in-hospital cardiac resynchronization therapy (CRT) programme, including comprehensive heart failure (HF) evaluation and systematic echo-guided CRT optimization.
Methods And Results:
CRT implanted patients were referred for optimization programme at 3 to 12 months from implantation. The program included clinical and biological status, standardized screening for potential cause of CRT non-response and systematic echo-guided atrioventricular and interventricular delays (AVd and VVd) optimization. Initial CRT-response and improvement at 6 months post-optimization were assessed with a clinical composite score (CCS). Major HF events were tracked during 1 year after optimization. A total of 227 patients were referred for CRT optimization and enrolled (71 ± 11 years old, 77% male, LVEF 30.6 ± 7.9%), of whom 111 (48.9%) were classified as initial non-responders. Left ventricular lead dislodgement was noted in 4 patients (1.8%), and loss or ≤90% biventricular capture in 22 (9.7%), mostly due to arrhythmias. Of the 196 patients (86%) who could undergo echo-guided CRT optimization, 71 (36.2%) required VVd modification and 50/144 (34.7%) AVd modification. At 6 months post-optimization, 34.3% of the initial non-responders were improved according to the CCS, but neither AVd nor VVd echo-guided modification was significantly associated with CCS-improvement. After one-year follow-up, initial non-responders maintained a higher rate of major HF events than initial responders, with no significant difference between AVd/VVd modified or not.
Conclusions:
Our study supports the necessity of a close, comprehensive and multidisciplinary follow-up of CRT patients, without arguing for routine use of echo-guided CRT optimization.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy II: Dilated Cardiomyopathy


